MetaCap

Organigram Global (OGI) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Organigram Global (OGI) has outperformed Upstream Bio (UPB) over the past year, losing 60.6% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $82.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OGI-60.61%UPB-93.78%
+49%-26%-101%
Nov 21, 20251 yearNov 20, 2026
OGI-66.10%UPB-92.77%
+48%-26%-99%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OGI versus UPB key metrics
MetricOGIUPB
Share price$0.583$1.59
Market cap$82.27M$87.15M
1-day change-7.40%-20.50%
YTD return-65.30%-94.14%
1-year return-60.61%-93.78%
5-year return-93.25%—
P/E ratio (TTM)1.36—
Forward P/E27.76—
EPS (TTM)$0.43$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)—$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$2.24$33.68
52-week low$0.583$1.56
Distance from 52-week high-73.97%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside—+1245.91%
Average volume567.77K1.01M
Shares outstanding141.11M54.81M
Employees1,13975
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OGI has outperformed UPB by 33.2 percentage points over the past year.

About Organigram Global

OGI stock →

Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

OGI vs UPB FAQ

Which is bigger, Organigram Global or Upstream Bio?

Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $82.27M for Organigram Global (OGI).

Which stock has performed better over the past year, OGI or UPB?

OGI returned -60.61% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are Organigram Global and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons